ArticleJournal of medical case reports2024
Depression, post-traumatic stress disorder, suicidal ideation and ketamine: a case report.
Article in Journal of medical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKetamine treatment presents a novel approach for addressing refractory conditions, such as major depressive disorder, suicidal ideation, and posttraumatic stress disorder, which often co-occur and pose significant challenges for clinicians. This study explores the clinical and electrophysiological outcomes of ketamine treatment in two cases, shedding light on its potential efficacy and mechanisms of action. CASE PRESENTATION: The first case involves a 56-year-old Caucasian male with chronic posttraumatic stress disorder and suicidal ideation, and the second case involves a 52-year-old Caucasian female with treatment-resistant major depressive disorder. Both patients opted for ketamine treatment after years of unsuccessful interventions. The male patient received nine ketamine infusions over 18 months, while the female patient received five infusions over one month. Symptom improvement was accompanied by distinct electrophysiological changes, as observed through electroencephalogram and evoked electroencephalogram responses. These changes persisted for several months post-treatment, offering hope for individuals grappling with challenging chronic conditions.
conclusionKetamine infusions resulted in significant and sustained symptomatic improvement in both cases, accompanied by distinct electrophysiological changes indicative of altered brain function. These findings highlight the potential of ketamine as an alternative treatment for refractory conditions, such as major depressive disorder and posttraumatic stress disorder, offering relief and functional recovery for certain patients. Further research is warranted to elucidate the underlying mechanisms and optimize treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.